Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab

Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including recurrent or metastatic head and neck cancer (R/M HNSCC) treated with nivolumab, the usefulness of the pretreatment C-reactive protein/albumin ratio...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 11; no. 1; p. 2741
Main Authors Tanoue, Kenro, Tamura, Shingo, Kusaba, Hitoshi, Shinohara, Yudai, Ito, Mamoru, Tsuchihashi, Kenji, Shirakawa, Tsuyoshi, Otsuka, Taiga, Ohmura, Hirofumi, Isobe, Taichi, Ariyama, Hiroshi, Koreishi, Sakuya, Matsushita, Yuzo, Shimokawa, Hozumi, Tanaka, Risa, Mitsugi, Kenji, Akashi, Koichi, Baba, Eishi
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 02.02.2021
Nature Publishing Group
Nature Portfolio
Subjects
631/67/1536
631/67/1857
631/67/580
Albumin
C-reactive protein
Disease control
Head & neck cancer
Humanities and Social Sciences
Immunotherapy
Leukocytes (neutrophilic)
Lymphocytes
Medical prognosis
Metastases
Metastasis
Monoclonal antibodies
multidisciplinary
Science
Science (multidisciplinary)
Squamous cell carcinoma
Targeted cancer therapy
Online AccessGet full text

Cover

Abstract Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including recurrent or metastatic head and neck cancer (R/M HNSCC) treated with nivolumab, the usefulness of the pretreatment C-reactive protein/albumin ratio (CAR) as a prognostic marker remains to be clarified. This study aimed to analyze the clinical usability of the CAR in comparison with that of the NLR. 46 R/M HNSCC patients treated with nivolumab were retrospectively analyzed. The optimal cutoff value for the CAR was calculated using receiver operating characteristic curve analysis. The optimal cutoff value for the CAR was set to 0.30. On multivariate analyses, a high CAR was significantly associated with poor overall survival (adjusted HR, 2.19; 95% CI, 1.42–3.47; p  < 0.01) and progression-free survival (adjusted HR, 1.98; 95% CI, 1.38–2.80; p  < 0.01). The overall response rate and disease control rate for the high CAR patients were lower than for the low CAR patients. The CAR had significantly higher area under the curve values than the NLR at 2 and 4 months. The pretreatment CAR might be an independent marker for prognosis and efficacy in R/M HNSCC patients treated with nivolumab.
AbstractList Abstract Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including recurrent or metastatic head and neck cancer (R/M HNSCC) treated with nivolumab, the usefulness of the pretreatment C-reactive protein/albumin ratio (CAR) as a prognostic marker remains to be clarified. This study aimed to analyze the clinical usability of the CAR in comparison with that of the NLR. 46 R/M HNSCC patients treated with nivolumab were retrospectively analyzed. The optimal cutoff value for the CAR was calculated using receiver operating characteristic curve analysis. The optimal cutoff value for the CAR was set to 0.30. On multivariate analyses, a high CAR was significantly associated with poor overall survival (adjusted HR, 2.19; 95% CI, 1.42–3.47; p  < 0.01) and progression-free survival (adjusted HR, 1.98; 95% CI, 1.38–2.80; p  < 0.01). The overall response rate and disease control rate for the high CAR patients were lower than for the low CAR patients. The CAR had significantly higher area under the curve values than the NLR at 2 and 4 months. The pretreatment CAR might be an independent marker for prognosis and efficacy in R/M HNSCC patients treated with nivolumab.
Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including recurrent or metastatic head and neck cancer (R/M HNSCC) treated with nivolumab, the usefulness of the pretreatment C-reactive protein/albumin ratio (CAR) as a prognostic marker remains to be clarified. This study aimed to analyze the clinical usability of the CAR in comparison with that of the NLR. 46 R/M HNSCC patients treated with nivolumab were retrospectively analyzed. The optimal cutoff value for the CAR was calculated using receiver operating characteristic curve analysis. The optimal cutoff value for the CAR was set to 0.30. On multivariate analyses, a high CAR was significantly associated with poor overall survival (adjusted HR, 2.19; 95% CI, 1.42–3.47; p < 0.01) and progression-free survival (adjusted HR, 1.98; 95% CI, 1.38–2.80; p < 0.01). The overall response rate and disease control rate for the high CAR patients were lower than for the low CAR patients. The CAR had significantly higher area under the curve values than the NLR at 2 and 4 months. The pretreatment CAR might be an independent marker for prognosis and efficacy in R/M HNSCC patients treated with nivolumab.
Abstract Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including recurrent or metastatic head and neck cancer (R/M HNSCC) treated with nivolumab, the usefulness of the pretreatment C-reactive protein/albumin ratio (CAR) as a prognostic marker remains to be clarified. This study aimed to analyze the clinical usability of the CAR in comparison with that of the NLR. 46 R/M HNSCC patients treated with nivolumab were retrospectively analyzed. The optimal cutoff value for the CAR was calculated using receiver operating characteristic curve analysis. The optimal cutoff value for the CAR was set to 0.30. On multivariate analyses, a high CAR was significantly associated with poor overall survival (adjusted HR, 2.19; 95% CI, 1.42–3.47; p < 0.01) and progression-free survival (adjusted HR, 1.98; 95% CI, 1.38–2.80; p < 0.01). The overall response rate and disease control rate for the high CAR patients were lower than for the low CAR patients. The CAR had significantly higher area under the curve values than the NLR at 2 and 4 months. The pretreatment CAR might be an independent marker for prognosis and efficacy in R/M HNSCC patients treated with nivolumab.
Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including recurrent or metastatic head and neck cancer (R/M HNSCC) treated with nivolumab, the usefulness of the pretreatment C-reactive protein/albumin ratio (CAR) as a prognostic marker remains to be clarified. This study aimed to analyze the clinical usability of the CAR in comparison with that of the NLR. 46 R/M HNSCC patients treated with nivolumab were retrospectively analyzed. The optimal cutoff value for the CAR was calculated using receiver operating characteristic curve analysis. The optimal cutoff value for the CAR was set to 0.30. On multivariate analyses, a high CAR was significantly associated with poor overall survival (adjusted HR, 2.19; 95% CI, 1.42–3.47; p  < 0.01) and progression-free survival (adjusted HR, 1.98; 95% CI, 1.38–2.80; p  < 0.01). The overall response rate and disease control rate for the high CAR patients were lower than for the low CAR patients. The CAR had significantly higher area under the curve values than the NLR at 2 and 4 months. The pretreatment CAR might be an independent marker for prognosis and efficacy in R/M HNSCC patients treated with nivolumab.
Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including recurrent or metastatic head and neck cancer (R/M HNSCC) treated with nivolumab, the usefulness of the pretreatment C-reactive protein/albumin ratio (CAR) as a prognostic marker remains to be clarified. This study aimed to analyze the clinical usability of the CAR in comparison with that of the NLR. 46 R/M HNSCC patients treated with nivolumab were retrospectively analyzed. The optimal cutoff value for the CAR was calculated using receiver operating characteristic curve analysis. The optimal cutoff value for the CAR was set to 0.30. On multivariate analyses, a high CAR was significantly associated with poor overall survival (adjusted HR, 2.19; 95% CI, 1.42-3.47; p < 0.01) and progression-free survival (adjusted HR, 1.98; 95% CI, 1.38-2.80; p < 0.01). The overall response rate and disease control rate for the high CAR patients were lower than for the low CAR patients. The CAR had significantly higher area under the curve values than the NLR at 2 and 4 months. The pretreatment CAR might be an independent marker for prognosis and efficacy in R/M HNSCC patients treated with nivolumab.
ArticleNumber 2741
Author Mitsugi, Kenji
Otsuka, Taiga
Tamura, Shingo
Ito, Mamoru
Shirakawa, Tsuyoshi
Baba, Eishi
Tanaka, Risa
Tsuchihashi, Kenji
Koreishi, Sakuya
Isobe, Taichi
Shimokawa, Hozumi
Ohmura, Hirofumi
Kusaba, Hitoshi
Shinohara, Yudai
Ariyama, Hiroshi
Tanoue, Kenro
Akashi, Koichi
Matsushita, Yuzo
Author_xml – sequence: 1
  givenname: Kenro
  surname: Tanoue
  fullname: Tanoue, Kenro
  organization: Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University
– sequence: 2
  givenname: Shingo
  surname: Tamura
  fullname: Tamura, Shingo
  organization: Department of Medical Oncology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center
– sequence: 3
  givenname: Hitoshi
  surname: Kusaba
  fullname: Kusaba, Hitoshi
  organization: Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital
– sequence: 4
  givenname: Yudai
  surname: Shinohara
  fullname: Shinohara, Yudai
  organization: Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital
– sequence: 5
  givenname: Mamoru
  surname: Ito
  fullname: Ito, Mamoru
  organization: Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital
– sequence: 6
  givenname: Kenji
  surname: Tsuchihashi
  fullname: Tsuchihashi, Kenji
  organization: Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital
– sequence: 7
  givenname: Tsuyoshi
  surname: Shirakawa
  fullname: Shirakawa, Tsuyoshi
  organization: Karatsu Higashi-Matsuura Medical Association Center
– sequence: 8
  givenname: Taiga
  surname: Otsuka
  fullname: Otsuka, Taiga
  organization: Department of Internal Medicine, Minato Medical Clinic
– sequence: 9
  givenname: Hirofumi
  surname: Ohmura
  fullname: Ohmura, Hirofumi
  organization: Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University
– sequence: 10
  givenname: Taichi
  surname: Isobe
  fullname: Isobe, Taichi
  organization: Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University
– sequence: 11
  givenname: Hiroshi
  surname: Ariyama
  fullname: Ariyama, Hiroshi
  organization: Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital
– sequence: 12
  givenname: Sakuya
  surname: Koreishi
  fullname: Koreishi, Sakuya
  organization: Department of Medical Oncology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center
– sequence: 13
  givenname: Yuzo
  surname: Matsushita
  fullname: Matsushita, Yuzo
  organization: Department of Medical Oncology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center
– sequence: 14
  givenname: Hozumi
  surname: Shimokawa
  fullname: Shimokawa, Hozumi
  organization: Department of Medical Oncology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center
– sequence: 15
  givenname: Risa
  surname: Tanaka
  fullname: Tanaka, Risa
  organization: Department of Medical Oncology, Hamanomachi Hospital
– sequence: 16
  givenname: Kenji
  surname: Mitsugi
  fullname: Mitsugi, Kenji
  organization: Department of Medical Oncology, Hamanomachi Hospital
– sequence: 17
  givenname: Koichi
  surname: Akashi
  fullname: Akashi, Koichi
  organization: Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University
– sequence: 18
  givenname: Eishi
  surname: Baba
  fullname: Baba, Eishi
  email: e-baba@intmed1.med.kyushu-u.ac.jp
  organization: Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33531609$$D View this record in MEDLINE/PubMed
BookMark eNp9Uk1v1TAQjFARLaV_gAOyxIVLwHZsx7kgoSc-KlWCA5ytjbN-dUnsVzt5Uv8Evxm_ppSWA754tTs79ozmeXUUYsCqesnoW0Yb_S4LJjtdU85qzYXQNXtSnXAqZM0bzo8e1MfVWc5XtBzJO8G6Z9Vx08iGKdqdVL--JRy8nf0eiZ92YGcSHdnUCWFt7lKc0QcyRwJjv0ylTDD7SFxMJKFdUsJQlhKZcIY8l5kllwgDgTCQgPYnydcLTHHJxOI4EgvJ-hAnOGyj3_uwJcHv47hM0L-onjoYM57d3afVj08fv2--1BdfP59vPlzUVlE110U7sKEDzhygg4arTkEndY-ao-j7QXStkJoKbtG1jvZFuALVOmeV6gRtTqvzlXeIcGV2yU-QbkwEb24bMW0NpKJkREN1RzVlhVz2QjLZO-ucdtJSzbpiauF6v3Ltln7CwRY7EoyPSB9Pgr8027g3rZZCMVUI3twRpHi9YJ7N5PPBKwhYbDNcaMWkbNumQF__A72KSwrFqgNKNlxyqQuKryibYs4J3f1nGDWH9Jg1Paakx9ymx7Cy9OqhjPuVP1kpgGYF5DIKW0x_3_4P7W9ladPP
CitedBy_id crossref_primary_10_3390_cancers14030472
crossref_primary_10_2147_OTT_S373631
crossref_primary_10_3390_cancers16132424
crossref_primary_10_1007_s00432_023_05504_5
crossref_primary_10_5981_jjhnc_48_1
crossref_primary_10_1186_s13000_023_01335_7
crossref_primary_10_3390_cancers14184413
crossref_primary_10_3389_fonc_2023_1148786
crossref_primary_10_3892_ol_2022_13377
crossref_primary_10_3390_cancers15072021
crossref_primary_10_1007_s00262_022_03265_7
crossref_primary_10_1007_s12672_023_00774_4
crossref_primary_10_1002_hed_26997
crossref_primary_10_3390_jcm11206100
crossref_primary_10_1016_j_jormas_2024_101961
crossref_primary_10_3390_jcm13092456
crossref_primary_10_3389_fimmu_2023_1113369
crossref_primary_10_3390_diagnostics13162620
crossref_primary_10_1097_CJI_0000000000000529
Cites_doi 10.1002/hed.25737
10.1016/j.cllc.2017.09.002
10.1186/s12885-015-1379-6
10.1245/s10434-014-4048-0
10.1038/srep10481
10.1158/0008-5472.CAN-18-0118
10.1002/cncr.23615
10.1056/NEJMoa0802656
10.1016/j.lungcan.2017.07.024
10.1016/j.tranon.2015.06.006
10.1016/j.lungcan.2017.01.013
10.1056/NEJMoa1602252
10.3389/fonc.2019.01200
10.3322/caac.21492
10.2147/OTT.S128391
10.1002/hed.25565
10.1097/CMR.0000000000000333
10.1016/j.clgc.2017.12.015
10.1016/j.ejca.2008.10.026
10.1038/nature22079
10.1245/s10434-015-4948-7
10.1038/s41416-020-0810-1
10.1016/j.oraloncology.2014.04.003
10.1186/s12885-019-6373-y
10.2307/2531595
10.1200/JCO.2015.61.1509
10.1385/IR:23:1:41
10.1371/journal.pone.0138657
10.1007/s00268-016-3491-4
10.1038/nrdp.2017.105
10.1038/nrclinonc.2015.105
10.1002/jso.10269
10.1136/jitc-2020-000842
10.3390/cancers10120466
10.1093/jjco/hyy145
10.1038/s41598-017-02088-2
10.1186/1477-7819-9-18
10.1038/sj.bjc.6600257
10.1038/sj.bjc.6602248
ContentType Journal Article
Copyright The Author(s) 2021
The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2021
– notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
NPM
AAYXX
CITATION
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-021-82448-1
DatabaseName Springer Nature OA Free Journals
PubMed
CrossRef
ProQuest Central (Corporate)
ProQuest_Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
ProQuest Science Journals
Biological Science Database
ProQuest - Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
Publicly Available Content Database



PubMed
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 2741
ExternalDocumentID oai_doaj_org_article_089080158b5b4515bfcff8f5c0819000
10_1038_s41598_021_82448_1
33531609
Genre Journal Article
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ADBBV
ADRAZ
AENEX
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RIG
RNT
RNTTT
RPM
SNYQT
UKHRP
NPM
AAYXX
AFPKN
CITATION
7XB
8FK
K9.
PQEST
PQUKI
PRINS
Q9U
7X8
AFGXO
5PM
ID FETCH-LOGICAL-c606t-415a1d9a21faefa32696a958be82e4bbd497458042cef7f0b2946a67ffc669403
IEDL.DBID RPM
ISSN 2045-2322
IngestDate Thu Sep 05 15:44:10 EDT 2024
Tue Sep 17 21:20:05 EDT 2024
Sat Aug 17 01:44:42 EDT 2024
Thu Oct 10 22:51:23 EDT 2024
Fri Aug 23 01:03:27 EDT 2024
Wed Oct 16 00:45:24 EDT 2024
Fri Oct 11 20:36:29 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c606t-415a1d9a21faefa32696a958be82e4bbd497458042cef7f0b2946a67ffc669403
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854616/
PMID 33531609
PQID 2485325258
PQPubID 2041939
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_089080158b5b4515bfcff8f5c0819000
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7854616
proquest_miscellaneous_2486155773
proquest_journals_2485325258
crossref_primary_10_1038_s41598_021_82448_1
pubmed_primary_33531609
springer_journals_10_1038_s41598_021_82448_1
PublicationCentury 2000
PublicationDate 2021-02-02
PublicationDateYYYYMMDD 2021-02-02
PublicationDate_xml – month: 02
  year: 2021
  text: 2021-02-02
  day: 02
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2021
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Baracos (CR20) 2018; 4
Chung (CR35) 2003; 83
Ferris (CR3) 2016; 375
Ravishankaran (CR32) 2011; 9
Eisenhauer (CR40) 2009; 45
Liu (CR11) 2015; 8
Laino (CR37) 2020; 8
Yoshida (CR33) 2002; 86
Ishizuka (CR12) 2016; 23
Sun (CR26) 2017; 2017
Zandberg (CR4) 2014; 50
Xu (CR15) 2015; 10
McKeown (CR34) 2004; 91
Ohmura (CR39) 2020; 122
Yasumatsu (CR10) 2019; 41
Riedel (CR31) 2005; 25
Kuboki (CR18) 2019; 41
Duffy (CR30) 2008; 113
De Long (CR41) 1988; 44
Wei (CR13) 2015; 15
Pettersen (CR29) 2017; 7
Huang (CR5) 2017; 545
Yu (CR22) 2017; 10
Inoue (CR27) 2018; 19
Kinoshita (CR14) 2015; 22
Bagley (CR8) 2017; 106
Crusz (CR19) 2015; 12
Lino-Silva (CR6) 2017; 27
Haruki (CR17) 2016; 40
Zhou (CR16) 2015; 5
Matsuzaka (CR23) 2019; 49
Diem (CR7) 2017; 111
Vermorken (CR2) 2008; 359
Martin (CR24) 2019; 9
Liu (CR25) 2019; 19
Bray (CR1) 2018; 68
Tsukamoto (CR38) 2018; 78
Bilen (CR9) 2018; 16
Nishikawa (CR21) 2018; 10
Barton (CR36) 2001; 23
Ferris (CR28) 2015; 33
X Liu (82448_CR11) 2015; 8
S Crusz (82448_CR19) 2015; 12
ER De Long (82448_CR41) 1988; 44
A Huang (82448_CR5) 2017; 545
T Zhou (82448_CR16) 2015; 5
D Martin (82448_CR24) 2019; 9
Z Liu (82448_CR25) 2019; 19
MA Bilen (82448_CR9) 2018; 16
H Ohmura (82448_CR39) 2020; 122
F Bray (82448_CR1) 2018; 68
P Ravishankaran (82448_CR32) 2011; 9
XL Wei (82448_CR13) 2015; 15
V Baracos (82448_CR20) 2018; 4
M Ishizuka (82448_CR12) 2016; 23
A Kuboki (82448_CR18) 2019; 41
JB Vermorken (82448_CR2) 2008; 359
AS Laino (82448_CR37) 2020; 8
DJ McKeown (82448_CR34) 2004; 91
YC Chung (82448_CR35) 2003; 83
H Tsukamoto (82448_CR38) 2018; 78
RL Ferris (82448_CR3) 2016; 375
LS Lino-Silva (82448_CR6) 2017; 27
ST Yu (82448_CR22) 2017; 10
R Yasumatsu (82448_CR10) 2019; 41
D Nishikawa (82448_CR21) 2018; 10
SJ Bagley (82448_CR8) 2017; 106
T Matsuzaka (82448_CR23) 2019; 49
T Inoue (82448_CR27) 2018; 19
K Haruki (82448_CR17) 2016; 40
RL Ferris (82448_CR28) 2015; 33
F Riedel (82448_CR31) 2005; 25
EA Eisenhauer (82448_CR40) 2009; 45
K Pettersen (82448_CR29) 2017; 7
S Diem (82448_CR7) 2017; 111
P Sun (82448_CR26) 2017; 2017
SA Duffy (82448_CR30) 2008; 113
BE Barton (82448_CR36) 2001; 23
N Yoshida (82448_CR33) 2002; 86
A Kinoshita (82448_CR14) 2015; 22
XL Xu (82448_CR15) 2015; 10
DP Zandberg (82448_CR4) 2014; 50
References_xml – volume: 41
  start-page: 2610
  year: 2019
  end-page: 2618
  ident: CR10
  article-title: Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer
  publication-title: Head Neck
  doi: 10.1002/hed.25737
  contributor:
    fullname: Yasumatsu
– volume: 19
  start-page: e171
  year: 2018
  end-page: e176
  ident: CR27
  article-title: Analysis of early death in Japanese patients with advanced non-small-cell lung cancer treated with nivolumab
  publication-title: Clin. Lung Cancer
  doi: 10.1016/j.cllc.2017.09.002
  contributor:
    fullname: Inoue
– volume: 15
  start-page: 350
  year: 2015
  ident: CR13
  article-title: A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio
  publication-title: BMC Cancer
  doi: 10.1186/s12885-015-1379-6
  contributor:
    fullname: Wei
– volume: 22
  start-page: 803
  year: 2015
  end-page: 810
  ident: CR14
  article-title: The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma
  publication-title: Ann. Surg. Oncol.
  doi: 10.1245/s10434-014-4048-0
  contributor:
    fullname: Kinoshita
– volume: 5
  start-page: 10481
  year: 2015
  ident: CR16
  article-title: Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer
  publication-title: Sci. Rep.
  doi: 10.1038/srep10481
  contributor:
    fullname: Zhou
– volume: 78
  start-page: 5011
  year: 2018
  end-page: 5022
  ident: CR38
  article-title: Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-18-0118
  contributor:
    fullname: Tsukamoto
– volume: 25
  start-page: 2761
  year: 2005
  end-page: 2765
  ident: CR31
  article-title: Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma
  publication-title: Anticancer Res.
  contributor:
    fullname: Riedel
– volume: 113
  start-page: 750
  year: 2008
  end-page: 757
  ident: CR30
  article-title: Interleukin-6 predicts recurrence and survival among head and neck cancer patients
  publication-title: Cancer
  doi: 10.1002/cncr.23615
  contributor:
    fullname: Duffy
– volume: 359
  start-page: 1116
  year: 2008
  end-page: 1127
  ident: CR2
  article-title: Platinum-based chemotherapy plus cetuximab in head and neck cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0802656
  contributor:
    fullname: Vermorken
– volume: 111
  start-page: 176
  year: 2017
  end-page: 181
  ident: CR7
  article-title: Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
  publication-title: Lung Cancer (Amsterdam, Netherlands)
  doi: 10.1016/j.lungcan.2017.07.024
  contributor:
    fullname: Diem
– volume: 8
  start-page: 339
  year: 2015
  end-page: 345
  ident: CR11
  article-title: Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer
  publication-title: Transl. Oncol.
  doi: 10.1016/j.tranon.2015.06.006
  contributor:
    fullname: Liu
– volume: 106
  start-page: 1
  year: 2017
  end-page: 7
  ident: CR8
  article-title: Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2017.01.013
  contributor:
    fullname: Bagley
– volume: 375
  start-page: 1856
  year: 2016
  end-page: 1867
  ident: CR3
  article-title: Nivolumab for recurrent squamous-cell carcinoma of the head and neck
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1602252
  contributor:
    fullname: Ferris
– volume: 9
  start-page: 1200
  year: 2019
  ident: CR24
  article-title: C-reactive protein-to-albumin ratio as prognostic marker for anal squamous cell carcinoma treated with chemoradiotherapy
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2019.01200
  contributor:
    fullname: Martin
– volume: 68
  start-page: 394
  year: 2018
  end-page: 424
  ident: CR1
  article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21492
  contributor:
    fullname: Bray
– volume: 10
  start-page: 879
  year: 2017
  end-page: 884
  ident: CR22
  article-title: Prognostic value of the C-reactive protein/albumin ratio in patients with laryngeal squamous cell carcinoma
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S128391
  contributor:
    fullname: Yu
– volume: 41
  start-page: 1342
  year: 2019
  end-page: 1350
  ident: CR18
  article-title: Prognostic value of C-reactive protein/albumin ratio for patients with hypopharyngeal and laryngeal cancer undergoing invasive surgery involving laryngectomy
  publication-title: Head Neck
  doi: 10.1002/hed.25565
  contributor:
    fullname: Kuboki
– volume: 27
  start-page: 140
  year: 2017
  end-page: 144
  ident: CR6
  article-title: Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma
  publication-title: Melanoma Res.
  doi: 10.1097/CMR.0000000000000333
  contributor:
    fullname: Lino-Silva
– volume: 16
  start-page: e563
  year: 2018
  end-page: e575
  ident: CR9
  article-title: Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab
  publication-title: Clin. Genitourin. Cancer
  doi: 10.1016/j.clgc.2017.12.015
  contributor:
    fullname: Bilen
– volume: 45
  start-page: 228
  year: 2009
  end-page: 247
  ident: CR40
  article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2008.10.026
  contributor:
    fullname: Eisenhauer
– volume: 2017
  start-page: 6570808
  year: 2017
  ident: CR26
  article-title: The ratio of c-reactive protein/albumin is a novel inflammatory predictor of overall survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma
  publication-title: Dis. Mark.
  contributor:
    fullname: Sun
– volume: 545
  start-page: 60
  year: 2017
  end-page: 65
  ident: CR5
  article-title: T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
  publication-title: Nature
  doi: 10.1038/nature22079
  contributor:
    fullname: Huang
– volume: 23
  start-page: 900
  year: 2016
  end-page: 907
  ident: CR12
  article-title: Clinical significance of the C-reactive protein to albumin ratio for survival after surgery for colorectal cancer
  publication-title: Ann. Surg. Oncol.
  doi: 10.1245/s10434-015-4948-7
  contributor:
    fullname: Ishizuka
– volume: 122
  start-page: 1507
  year: 2020
  end-page: 1517
  ident: CR39
  article-title: OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-020-0810-1
  contributor:
    fullname: Ohmura
– volume: 50
  start-page: 627
  year: 2014
  end-page: 632
  ident: CR4
  article-title: The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck
  publication-title: Oral. Oncol.
  doi: 10.1016/j.oraloncology.2014.04.003
  contributor:
    fullname: Zandberg
– volume: 19
  start-page: 1161
  year: 2019
  ident: CR25
  article-title: Prognostic role of pre-treatment C-reactive protein/albumin ratio in esophageal cancer: a meta-analysis
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-6373-y
  contributor:
    fullname: Liu
– volume: 44
  start-page: 837
  year: 1988
  end-page: 845
  ident: CR41
  article-title: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach
  publication-title: Biometrics
  doi: 10.2307/2531595
  contributor:
    fullname: De Long
– volume: 33
  start-page: 3293
  year: 2015
  end-page: 3304
  ident: CR28
  article-title: Immunology and immunotherapy of head and neck cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.61.1509
  contributor:
    fullname: Ferris
– volume: 23
  start-page: 41
  year: 2001
  end-page: 58
  ident: CR36
  article-title: IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation
  publication-title: Immunol. Res.
  doi: 10.1385/IR:23:1:41
  contributor:
    fullname: Barton
– volume: 10
  start-page: e0138657
  year: 2015
  ident: CR15
  article-title: A novel inflammation-based prognostic score, the C-reactive protein/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0138657
  contributor:
    fullname: Xu
– volume: 40
  start-page: 2254
  year: 2016
  end-page: 2260
  ident: CR17
  article-title: The C-reactive protein to albumin ratio predicts long-term outcomes in patients with pancreatic cancer after pancreatic resection
  publication-title: World J. Surg.
  doi: 10.1007/s00268-016-3491-4
  contributor:
    fullname: Haruki
– volume: 4
  start-page: 17105
  year: 2018
  ident: CR20
  article-title: Cancer-associated cachexia
  publication-title: Nat. Rev. Dis. Primers
  doi: 10.1038/nrdp.2017.105
  contributor:
    fullname: Baracos
– volume: 12
  start-page: 584
  year: 2015
  end-page: 596
  ident: CR19
  article-title: Inflammation and cancer: advances and new agents
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2015.105
  contributor:
    fullname: Crusz
– volume: 83
  start-page: 222
  year: 2003
  end-page: 226
  ident: CR35
  article-title: Serum interleukin-6 levels reflect the disease status of colorectal cancer
  publication-title: J. Surg. Oncol.
  doi: 10.1002/jso.10269
  contributor:
    fullname: Chung
– volume: 8
  start-page: e000842
  year: 2020
  ident: CR37
  article-title: Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2020-000842
  contributor:
    fullname: Laino
– volume: 10
  start-page: 466
  year: 2018
  ident: CR21
  article-title: Prognostic markers in head and neck cancer patients treated with nivolumab
  publication-title: Cancers
  doi: 10.3390/cancers10120466
  contributor:
    fullname: Nishikawa
– volume: 49
  start-page: 37
  year: 2019
  end-page: 41
  ident: CR23
  article-title: Clinical impact of cachexia in unresectable locally advanced head and neck cancer: supplementary analysis of a phase II trial (JCOG0706-S2)
  publication-title: Jpn. J. Clin. Oncol.
  doi: 10.1093/jjco/hyy145
  contributor:
    fullname: Matsuzaka
– volume: 7
  start-page: 2046
  year: 2017
  ident: CR29
  article-title: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-02088-2
  contributor:
    fullname: Pettersen
– volume: 9
  start-page: 18
  year: 2011
  ident: CR32
  article-title: Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients
  publication-title: World J. Surg. Oncol.
  doi: 10.1186/1477-7819-9-18
  contributor:
    fullname: Ravishankaran
– volume: 86
  start-page: 1396
  year: 2002
  end-page: 1400
  ident: CR33
  article-title: Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6600257
  contributor:
    fullname: Yoshida
– volume: 91
  start-page: 1993
  year: 2004
  end-page: 1995
  ident: CR34
  article-title: The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6602248
  contributor:
    fullname: McKeown
– volume: 7
  start-page: 2046
  year: 2017
  ident: 82448_CR29
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-02088-2
  contributor:
    fullname: K Pettersen
– volume: 23
  start-page: 900
  year: 2016
  ident: 82448_CR12
  publication-title: Ann. Surg. Oncol.
  doi: 10.1245/s10434-015-4948-7
  contributor:
    fullname: M Ishizuka
– volume: 86
  start-page: 1396
  year: 2002
  ident: 82448_CR33
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6600257
  contributor:
    fullname: N Yoshida
– volume: 25
  start-page: 2761
  year: 2005
  ident: 82448_CR31
  publication-title: Anticancer Res.
  contributor:
    fullname: F Riedel
– volume: 375
  start-page: 1856
  year: 2016
  ident: 82448_CR3
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1602252
  contributor:
    fullname: RL Ferris
– volume: 44
  start-page: 837
  year: 1988
  ident: 82448_CR41
  publication-title: Biometrics
  doi: 10.2307/2531595
  contributor:
    fullname: ER De Long
– volume: 68
  start-page: 394
  year: 2018
  ident: 82448_CR1
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21492
  contributor:
    fullname: F Bray
– volume: 27
  start-page: 140
  year: 2017
  ident: 82448_CR6
  publication-title: Melanoma Res.
  doi: 10.1097/CMR.0000000000000333
  contributor:
    fullname: LS Lino-Silva
– volume: 10
  start-page: e0138657
  year: 2015
  ident: 82448_CR15
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0138657
  contributor:
    fullname: XL Xu
– volume: 45
  start-page: 228
  year: 2009
  ident: 82448_CR40
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2008.10.026
  contributor:
    fullname: EA Eisenhauer
– volume: 9
  start-page: 1200
  year: 2019
  ident: 82448_CR24
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2019.01200
  contributor:
    fullname: D Martin
– volume: 78
  start-page: 5011
  year: 2018
  ident: 82448_CR38
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-18-0118
  contributor:
    fullname: H Tsukamoto
– volume: 15
  start-page: 350
  year: 2015
  ident: 82448_CR13
  publication-title: BMC Cancer
  doi: 10.1186/s12885-015-1379-6
  contributor:
    fullname: XL Wei
– volume: 2017
  start-page: 6570808
  year: 2017
  ident: 82448_CR26
  publication-title: Dis. Mark.
  contributor:
    fullname: P Sun
– volume: 16
  start-page: e563
  year: 2018
  ident: 82448_CR9
  publication-title: Clin. Genitourin. Cancer
  doi: 10.1016/j.clgc.2017.12.015
  contributor:
    fullname: MA Bilen
– volume: 22
  start-page: 803
  year: 2015
  ident: 82448_CR14
  publication-title: Ann. Surg. Oncol.
  doi: 10.1245/s10434-014-4048-0
  contributor:
    fullname: A Kinoshita
– volume: 91
  start-page: 1993
  year: 2004
  ident: 82448_CR34
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6602248
  contributor:
    fullname: DJ McKeown
– volume: 83
  start-page: 222
  year: 2003
  ident: 82448_CR35
  publication-title: J. Surg. Oncol.
  doi: 10.1002/jso.10269
  contributor:
    fullname: YC Chung
– volume: 8
  start-page: e000842
  year: 2020
  ident: 82448_CR37
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2020-000842
  contributor:
    fullname: AS Laino
– volume: 19
  start-page: 1161
  year: 2019
  ident: 82448_CR25
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-6373-y
  contributor:
    fullname: Z Liu
– volume: 49
  start-page: 37
  year: 2019
  ident: 82448_CR23
  publication-title: Jpn. J. Clin. Oncol.
  doi: 10.1093/jjco/hyy145
  contributor:
    fullname: T Matsuzaka
– volume: 12
  start-page: 584
  year: 2015
  ident: 82448_CR19
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2015.105
  contributor:
    fullname: S Crusz
– volume: 23
  start-page: 41
  year: 2001
  ident: 82448_CR36
  publication-title: Immunol. Res.
  doi: 10.1385/IR:23:1:41
  contributor:
    fullname: BE Barton
– volume: 359
  start-page: 1116
  year: 2008
  ident: 82448_CR2
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa0802656
  contributor:
    fullname: JB Vermorken
– volume: 41
  start-page: 2610
  year: 2019
  ident: 82448_CR10
  publication-title: Head Neck
  doi: 10.1002/hed.25737
  contributor:
    fullname: R Yasumatsu
– volume: 545
  start-page: 60
  year: 2017
  ident: 82448_CR5
  publication-title: Nature
  doi: 10.1038/nature22079
  contributor:
    fullname: A Huang
– volume: 50
  start-page: 627
  year: 2014
  ident: 82448_CR4
  publication-title: Oral. Oncol.
  doi: 10.1016/j.oraloncology.2014.04.003
  contributor:
    fullname: DP Zandberg
– volume: 111
  start-page: 176
  year: 2017
  ident: 82448_CR7
  publication-title: Lung Cancer (Amsterdam, Netherlands)
  doi: 10.1016/j.lungcan.2017.07.024
  contributor:
    fullname: S Diem
– volume: 41
  start-page: 1342
  year: 2019
  ident: 82448_CR18
  publication-title: Head Neck
  doi: 10.1002/hed.25565
  contributor:
    fullname: A Kuboki
– volume: 10
  start-page: 466
  year: 2018
  ident: 82448_CR21
  publication-title: Cancers
  doi: 10.3390/cancers10120466
  contributor:
    fullname: D Nishikawa
– volume: 113
  start-page: 750
  year: 2008
  ident: 82448_CR30
  publication-title: Cancer
  doi: 10.1002/cncr.23615
  contributor:
    fullname: SA Duffy
– volume: 122
  start-page: 1507
  year: 2020
  ident: 82448_CR39
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-020-0810-1
  contributor:
    fullname: H Ohmura
– volume: 40
  start-page: 2254
  year: 2016
  ident: 82448_CR17
  publication-title: World J. Surg.
  doi: 10.1007/s00268-016-3491-4
  contributor:
    fullname: K Haruki
– volume: 19
  start-page: e171
  year: 2018
  ident: 82448_CR27
  publication-title: Clin. Lung Cancer
  doi: 10.1016/j.cllc.2017.09.002
  contributor:
    fullname: T Inoue
– volume: 33
  start-page: 3293
  year: 2015
  ident: 82448_CR28
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.61.1509
  contributor:
    fullname: RL Ferris
– volume: 106
  start-page: 1
  year: 2017
  ident: 82448_CR8
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2017.01.013
  contributor:
    fullname: SJ Bagley
– volume: 8
  start-page: 339
  year: 2015
  ident: 82448_CR11
  publication-title: Transl. Oncol.
  doi: 10.1016/j.tranon.2015.06.006
  contributor:
    fullname: X Liu
– volume: 4
  start-page: 17105
  year: 2018
  ident: 82448_CR20
  publication-title: Nat. Rev. Dis. Primers
  doi: 10.1038/nrdp.2017.105
  contributor:
    fullname: V Baracos
– volume: 9
  start-page: 18
  year: 2011
  ident: 82448_CR32
  publication-title: World J. Surg. Oncol.
  doi: 10.1186/1477-7819-9-18
  contributor:
    fullname: P Ravishankaran
– volume: 5
  start-page: 10481
  year: 2015
  ident: 82448_CR16
  publication-title: Sci. Rep.
  doi: 10.1038/srep10481
  contributor:
    fullname: T Zhou
– volume: 10
  start-page: 879
  year: 2017
  ident: 82448_CR22
  publication-title: Onco Targets Ther.
  doi: 10.2147/OTT.S128391
  contributor:
    fullname: ST Yu
SSID ssj0000529419
Score 2.4696016
Snippet Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including...
Abstract Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer,...
Abstract Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer,...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 2741
SubjectTerms 631/67/1536
631/67/1857
631/67/580
Albumin
C-reactive protein
Disease control
Head & neck cancer
Humanities and Social Sciences
Immunotherapy
Leukocytes (neutrophilic)
Lymphocytes
Medical prognosis
Metastases
Metastasis
Monoclonal antibodies
multidisciplinary
Science
Science (multidisciplinary)
Squamous cell carcinoma
Targeted cancer therapy
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9UwFA4yILgR31ZHieBOy7RJ81rq4DAIigsHZheSNMEik6v3dhb-CX-z5yS917k-cOOuTVo4nPdJcr4Q8hxB7HopXRuT4-0Apt0ibHnLEBF37HzQAZuT372Xp2fD23NxfuWqLzwTVuGBK-OOOm0gqemF9sIPEHx9CinpJEKJZV2t1ntxpZiqqN7MDL1ZumQ6ro82EKmwm4z1rYaQBqXTXiQqgP1_yjJ_Pyz5y45pCUQnt8jNJYOkryrlt8m1mO-Q6_VOyW93yfcPa9x7QS9GawskXSV63EJyWAcLMsOU6byi5WwyPBYtoJC-0jUuvyNgE4WXizg7bDiaAgWXPVKXR5pj-Ew3Xy8dLhlQXPanAa8jyqsLh3_HCVcoaJ6K23P-Hjk7efPx-LRdLl1oA9Qycwtscv1oHOuTQ_kxaaQzwP6oWRy8HweoQIQGWw8xqdR5YLR0UqUUpDRDx--Tg7zK8SGhyjM9QgxmKvEhCOXTyJWHQeOS5NE15MVWAPZLxdawZU-ca1vFZUFctojL9g15jTLafYm42GUAtMUu2mL_pS0NOdxK2C7GurGI6saZYEI35NluGswMmehyBH7iN7iDqxRvyIOqEDtKOAdHJjvTELWnKnuk7s_k6VOB8lZaDLKXDXm5VaqfZP2dFY_-BysekxsMrQFPoLNDcjCvL-MTSLBm_7TY0g_u5CMf
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest_Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkLKu-0BRmJG1hN7MR2TqitqCokEAcq7c2yHRsiVKfdTQ_8CX5zZ5zsVsvrtutkJe-8PeP5hpA3CGJXSWlZiFawGlSbIWw544iI25XOa4_NyZ8-y7Pz-uOiWcwJt9V8rXJtE7Oh7gaPOfJDhN4SvOGNfn95xXBqFFZX5xEad8m9ikMwAfKsFmqTY8EqVl21c69MKfThCvwV9pTximlwbHCA2vJHGbb_b7Hmn1cmf6ubZnd0ukseznEkPZoY_4jcCekxuT9Nlvz5hPz6ssQKDNoyOjVC0iHSEwYh4rSY8Rn6RMeB5hvK8DHLAoUgli4xCY-wTRS-XITRYttR7ykY7o7a1NEU_A-6urq2mDigmPynHocSpeHC4q9Dj3kKmvps_Kx7Ss5PP3w9OWPz6AXm4UQzMiCTrbrW8ipa5CKXrbRto13QPNTOdTWcQxoNGu9DVLF0QGhppYrRS9nWpXhGdtKQwgtCleO6A0_MVRS1b5SLnVAOFlsbpQi2IG_XDDCXE8KGyZVxoc3ELgPsMpldpirIMfJo8yaiY-eFYfnNzMpmSt1CIFzBdhtXQ8Dmoo9Rx8bn-KcsC3Kw5rCZVXZlbgWsIK83j0HZkIg2BaAnvoN1XKVEQZ5PArHZiRBgzmTZFkRticrWVrefpP57BvRWuqllJQvybi1Ut9v6Nyn2_v8v9skDjnKON8z5AdkZl9fhJQRQo3uVteQGEc4brw
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9UwFA9zIvgy_LZzSgTftNomaZI-iOhwDGHigxf2FpI0cRdd63o7cP-Ef7PnpO2Vq9c339qkhXC-k5PzO4Q8QxC7Ukqbh2h5LkC1c4Qtzxki4jaF89pjcfLJR3m8EB9Oq9MdMrc7mgi42rq1w35Si_7byx8XV29A4V-PJeP61QqcEBaKsTLX4K1gV3SNXGeCC5T4kyncH7G-WS3Keqqd2f7rhn9KMP7bYs-_r1D-kUdN7unoFtmb4kr6dhSE22QntHfIjbHT5NVd8vNTjxkZtG10LIykXaSHOYSM42DCa1i2dOhourEMj0k2KAS1tMdDeYRxovByHgaLZUhLT8GQN9S2DW2D_0pXF5cWDxIoJgOoxyZFbXdu8e-wxHML2i6TMbTuHlkcvf98eJxPrRhyDzucIQcy2bKpLSujRa4yWUtbV9oFzYJwrhGwL6k0WAAfooqFA0JLK1WMXspaFPw-2W27NjwkVDmmG_DMTEUufKVcbLhyMFjbKHmwGXk-M8B8HxE3TMqUc21Gdhlgl0nsMmVG3iGP1l8iWnYa6PovZlI-U-gaAuMSlls5AQGciz5GHSuf4qGiyMjBzGEzS6BBrDfOKlbpjDxdT4PyIRFtG4Ce-A3mdZXiGXkwCsR6JZyDeZNFnRG1ISobS92caZdnCeBb6UrIUmbkxSxUv5f1b1Ls_w9SPCI3GWoD3ktnB2R36C_DYwi7Bvck6dIvdYIrYg
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagCIkL4k1KQUbiBhaJHT9yhBVVhQTiQKXeLNuxRYTqLbvpgT_Bb-6Mk10UKAduiR-SNQ_PeMbzmZBXCGLXKOVYTE6wFlSbIWw544iI29c-mIDFyZ8-q5PT9uOZPJthcrAWZpG_F-btFgwMFoHxhhmwRHDiuUluyUbVKMErtdrHUzBj1TbdXBdz_dSF7SkQ_df5lX9fj_wjR1pMz_E9cnf2Gem7icn3yY2YH5Db0yuSPx-SX182mG3BfYtORY90neiKgTs4NRYshiHTcU3LbWT4LHyn4LDSDQbcEaKJws95HB2WGA2BwibdU5d7mmP4Trc_Lh0GCSgG-mnAB4jy-tzh7DhgTILmoWx0zj8ip8cfvq5O2PzMAgtwehkZkMk1fed4kxxyjKtOuU4aHw2Prfd9C2cOaUC7Q0w61R4IrZzSKQWlurYWj8lBXuf4lFDtuenB6nKdRBuk9qkX2kNj55IS0VXk9Y4B9mJC07AlCy6MndhlgV22sMs2FXmPPNqPRCTs0gACYmfFsrXpwOltYLnSt-Cc-RRSMkmG4uvUdUWOdhy2s3puLeK4CS65NBV5ue8GxUIiuhyBnjgGc7Zai4o8mQRivxIhYOsCGayIXojKYqnLnjx8K-Dd2shWNaoib3ZC9XtZ_ybF4f8Nf0bucJR7vF3Oj8jBuLmMz8F5Gv2LojVXlCQUng
  priority: 102
  providerName: Springer Nature
Title Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
URI https://link.springer.com/article/10.1038/s41598-021-82448-1
https://www.ncbi.nlm.nih.gov/pubmed/33531609
https://www.proquest.com/docview/2485325258
https://search.proquest.com/docview/2486155773
https://pubmed.ncbi.nlm.nih.gov/PMC7854616
https://doaj.org/article/089080158b5b4515bfcff8f5c0819000
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELe2IdBeEN8ERmUk3iBrYie288iqTRNSpwoxqW-R7dgsgrqj7R74J_ibuXOSsvLxwkvUOIl6ug_f-Xz3MyFvEMQuF0KnzmueFmDaKcKWpwwRcZvMWGWxOXl6Ic4viw_zcr5HyqEXJhbtW9Meh6-L49BexdrK64UdD3Vi49l0IlVZiFyM98m-5PzWEr0D9GZVkVd9g0zG1XgNTgobyVieKvBmsGo6JPc4B-0TWId4yx9F2P6_xZp_lkz-tm8a3dHZA3K_jyPp-47eh2TPhUfkbney5PfH5MdshTswOJfRrhGSLj2dpBAidoMRn6ENdLOksUIZfkZdoBDE0hUm4RG2icLNwm00th21lsLE3VAdGhqc_ULX3240Jg4oJv-pxUOJwnKh8WvXYp6ChjZOfto8IZdnp58m52l_9EJqYUWzSYFjOm8qzXKvUYpMVEJXpTJOMVcY0xSwDikVWLx1XvrMAM-FFtJ7K0RVZPwpOQjL4J4TKg1TDXhiJj0vbCmNb7g0MFhpL7jTCXk7CKC-7hA26rgzzlXdSa4GydVRcnWekBOU0fZNRMeOA8vV57rXkTpTFQTCOZBbmgICNuOt98qXNsY_WZaQo0HCdW-y6xqx3TgrWakS8nr7GIwNmaiDA37iO7iPKyVPyLNOIbaUDAqVELmjKjuk7j4B_Y6A3r0-J-TdoFS_yPo3K1789x-9JIcMrQGLz9kROdisbtwriK02ZgQWNZcjcufk9GL2Ee4mYjKKeQq4Tgs1irb2Ez3kKds
link.rule.ids 230,315,733,786,790,870,891,2115,12083,21416,24346,27955,27956,31752,31753,33777,33778,41153,42222,43343,43838,51609,53825,53827,74100,74657
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCNEL4k2ggJG4QdTEdmznhKCiWqCtOLTS3izbsUuEmrS76aF_gt_MjJPdannddp2s5J23ZzzfEPIGQexKKW0eouW5ANXOEbY8Z4iI2xTOa4_NyYdHcnYivsyr-ZRwW07XKlc2MRnqpveYI99F6C3OKlbp9-cXOU6NwurqNELjJrklOBco52qu1jkWrGKJsp56ZQqud5fgr7CnjJW5BscGB6gNf5Rg-_8Wa_55ZfK3umlyR_v3yN0pjqQfRsbfJzdC94DcHidLXj0kP78tsAKDtoyOjZC0j3QvhxBxXEz4DG1Hh56mG8rwMckChSCWLjAJj7BNFL6chcFi21HrKRjuhtquoV3wP-jy4tJi4oBi8p96HErU9WcWfx1azFPQrk3Gz7pH5GT_0_HeLJ9GL-QeTjRDDmSyZVNbVkaLXGSylrautAuaBeFcI-AcUmnQeB-iioUDQksrVYxeyloU_DHZ6vouPCVUOaYb8MRMRS58pVxsuHKwWNsoebAZebtigDkfETZMqoxzbUZ2GWCXSewyZUY-Io_WbyI6dlroF6dmUjZT6BoC4RK2WzkBAZuLPkYdK5_in6LIyM6Kw2ZS2aW5FrCMvF4_BmVDItouAD3xHazjKsUz8mQUiPVOOAdzJos6I2pDVDa2uvmka78nQG-lKyFLmZF3K6G63ta_SfHs___iFbkzOz48MAefj74-J9sMZR5vm7MdsjUsLsMLCKYG9zJpzC-J-x6c
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCNQL4t1AASNxA2sTO7GdE4LCqryqHqi0N8t2bIhQk3Y3PfAn-M3MONmtltdt18lK3nl7ZvwNIc8RxK6Q0rIQrWAlqDZD2HLGERG3yZ3XHi8nfz6Shyflh0W1mPqfVlNb5domJkPd9B5z5DOE3hK84pWexakt4vjt_NXZOcMJUlhpncZpXCXXwEvmOMZBLdQm34IVrbKop3szudCzFfguvF_GC6bBycFhass3JQj_v8Wdf7ZP_lZDTa5pfovcnGJK-noUgtvkSujukOvjlMkfd8nP4yVWY9Cu0fFSJO0jPWAQLo6LCauh7ejQ09StDB-TXFAIaOkSE_II4UThy2kYLF5Baj0FI95Q2zW0C_47XZ1fWEwiUCwEUI8Dirr-1OKvQ4s5C9q1yRBad4-czN99OThk0xgG5uF0MzAgky2a2vIiWuQol7W0daVd0DyUzjUlnEkqDdrvQ1Qxd0BoaaWK0UtZl7m4T3a6vgt7hCrHdQNemasoSl8pFxuhHCzWNkoRbEZerBlgzka0DZOq5EKbkV0G2GUSu0yRkTfIo82biJSdFvrlVzMpnsl1DUFxAdutXAnBm4s-Rh0rn2KhPM_I_prDZlLflbkUtow82zwGxUMi2i4APfEdrOkqJTLyYBSIzU6EANMm8zojaktUtra6_aRrvyVwb6WrUhYyIy_XQnW5rX-T4uH__8VTcgOUxXx6f_TxEdnlKPLYeM73yc6wvAiPIa4a3JOkML8A28AiyA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictive+impact+of+C-reactive+protein+to+albumin+ratio+for+recurrent+or+metastatic+head+and+neck+squamous+cell+carcinoma+receiving+nivolumab&rft.jtitle=Scientific+reports&rft.au=Kenro+Tanoue&rft.au=Shingo+Tamura&rft.au=Hitoshi+Kusaba&rft.au=Yudai+Shinohara&rft.date=2021-02-02&rft.pub=Nature+Portfolio&rft.eissn=2045-2322&rft.volume=11&rft.issue=1&rft.spage=1&rft.epage=11&rft_id=info:doi/10.1038%2Fs41598-021-82448-1&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_089080158b5b4515bfcff8f5c0819000
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon